董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chen Yu | 男 | Director | 52 | 未披露 | 359.03 | 2026-09-28 |
| Erez Chimovits | 男 | Director and Interim Chairman of the Board | 62 | 未披露 | 923.05 | 2026-09-28 |
| Zhen Li | 女 | Chief Executive Officer and Director and President | 65 | 314.99万美元 | 1074.82 | 2026-09-28 |
| Simeon George | 男 | Director | 49 | 未披露 | 833.67 | 2026-09-28 |
| Judith J. Li | 女 | Director | 42 | 未披露 | 未持股 | 2026-09-28 |
| Ricky Sun | 男 | Director | 53 | 未披露 | 未持股 | 2026-09-28 |
| Ying Huang | 男 | Director | 53 | 未披露 | 未持股 | 2026-09-28 |
| Mary Tagliaferri | 女 | Director | 60 | 未披露 | 未持股 | 2026-09-28 |
| Ting Feng | 女 | Director | 43 | 未披露 | 未持股 | 2026-09-28 |
| Carl L. Gordon | 男 | Director | 61 | 未披露 | 2325.58 | 2026-09-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zhen Li | 女 | Chief Executive Officer and Director and President | 65 | 314.99万美元 | 1074.82 | 2026-09-28 |
| Ryan Fisk | 男 | Chief Business Officer and Chief Financial Officer | 44 | 未披露 | 未持股 | 2026-09-28 |
| Rui Zhu | 男 | Chief Technology Officer | 43 | 未披露 | 未持股 | 2026-09-28 |
| A. Robert MacLeod | 男 | Chief Scientific Officer | 59 | 86.80万美元 | 49.19 | 2026-09-28 |
| Robert Ackles | 男 | Chief People Officer | 61 | 未披露 | 未持股 | 2026-09-28 |
董事简历
中英对照 | 中文 | 英文- Chen Yu
-
Chen Yu，自2016年4月起担任董事会成员。Yu博士自2011年起担任Vivo Capital LLC （Vivo）的管理合伙人。在2004年加入Vivo之前，Yu博士曾任职于aQuantive（一家私人技术公司）。他曾担任China KangHui（中国领先的骨科公司）的首席商务官，以及Sagent Pharmaceuticals的首席运营官。他目前在美国和中国的几家私人生命科学公司任职，包括SentreHeart、Rempex Pharmaceuticals、Nora Therapeutics、Jian Rui Bao Beijing GMT science & Technology Development Co., Ltd 。、Outpost Medicine, LLC、PrinJohnson BioPharma, Inc.、Nabriva Therapeutics和Synaptic Medical。Yu博士目前任职于California Leadership Council for the Nature Conservancy（一个具有全球影响力的环境非营利组织），并曾担任Stanford Medical School校友理事会成员。Yu博士获得Stanford大学的医学博士和工商管理硕士学位，并以优异成绩毕业于Harvard大学的生物学学士学位。
Chen Yu has served as Tcgx Acquisition Corp. Ii's Chief Executive Officer and as a director since Tcgx Acquisition Corp. Ii's inception. Dr. Yu is the founder and Managing Member at TCGX, which was founded in January 2021, and has more than two decades of experience in healthcare investing, company building and operations. Prior to founding TCGX, Dr. Yu spent sixteen years as a Managing Partner at Vivo Capital LLC. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the Chief Operating Officer of Sagent Pharmaceuticals and Chief Business Officer of China KangHui, both of which went public and were ultimately acquired. Dr. Yu has led investments or served on the board of over a dozen private and public companies, including Abivax (NASDAQ:ABVX), Upstream Bio (NASDAQ:UPB) (from October 2021 to July 2024), Carmot (acquired by Roche), Structure Therapeutics (NASDAQ:GPCR) (from November 2021 to February 2023), Candid Therapeutics (acquired by UCB), ADARx Pharmaceuticals, Inc. (since 2023), Alkeus Pharmaceuticals, Inc. (since June 2023), Aviceda Therapeutics (since December 2024), Arbor Biotechnologies (from November 2021 to September 2025), Tarsus Pharmaceuticals (NASDAQ: TARS), Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi I Ko), China Kanghui (NYSE:KH, acquired by Medtronic), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), NKF Pharma (SHA: 603707), Pathalys Pharma, Inc. (since August 2024), LB Pharma (from November 2023 to September 2025), Artios Pharma Ltd. (from July 2021 to September 2025), Corxel Pharmaceuticals Limited (since January 2026), and TCGX Asia Life Sciences Partners I, Ltd. (since May 2026). Dr. Yu has also served on several committees of boards of directors, including the Compensation Committee of LB Pharma (from November 2023 to September 2025), the Audit Committee of Arbor Biotechnologies (from November 2021 to September 2025), and the Nomination and Governance Committee of Artios Pharma Ltd. (from July 2021 to September 2025). While at Vivo, Dr. Yu also led investments in Zai Labs (NASDAQ: ZLAB), RiverVision (acquired by Horizon), CRISPR Therapeutics (NASDAQ:CRSP), Intellia (NASDAQ: NTLA), Durata (acquired by Actavis), Trauson (acquired by Stryker), and Revolution Medicines (NASDAQ:RVMD). Dr. Yu also serves on the California Board of Trustees for the Nature Conservancy (since August 2025) and ElevAATe Biotechnology (since November 2024), and was previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University. - Chen Yu，自2016年4月起担任董事会成员。Yu博士自2011年起担任Vivo Capital LLC （Vivo）的管理合伙人。在2004年加入Vivo之前，Yu博士曾任职于aQuantive（一家私人技术公司）。他曾担任China KangHui（中国领先的骨科公司）的首席商务官，以及Sagent Pharmaceuticals的首席运营官。他目前在美国和中国的几家私人生命科学公司任职，包括SentreHeart、Rempex Pharmaceuticals、Nora Therapeutics、Jian Rui Bao Beijing GMT science & Technology Development Co., Ltd 。、Outpost Medicine, LLC、PrinJohnson BioPharma, Inc.、Nabriva Therapeutics和Synaptic Medical。Yu博士目前任职于California Leadership Council for the Nature Conservancy（一个具有全球影响力的环境非营利组织），并曾担任Stanford Medical School校友理事会成员。Yu博士获得Stanford大学的医学博士和工商管理硕士学位，并以优异成绩毕业于Harvard大学的生物学学士学位。
- Chen Yu has served as Tcgx Acquisition Corp. Ii's Chief Executive Officer and as a director since Tcgx Acquisition Corp. Ii's inception. Dr. Yu is the founder and Managing Member at TCGX, which was founded in January 2021, and has more than two decades of experience in healthcare investing, company building and operations. Prior to founding TCGX, Dr. Yu spent sixteen years as a Managing Partner at Vivo Capital LLC. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including stints as the Chief Operating Officer of Sagent Pharmaceuticals and Chief Business Officer of China KangHui, both of which went public and were ultimately acquired. Dr. Yu has led investments or served on the board of over a dozen private and public companies, including Abivax (NASDAQ:ABVX), Upstream Bio (NASDAQ:UPB) (from October 2021 to July 2024), Carmot (acquired by Roche), Structure Therapeutics (NASDAQ:GPCR) (from November 2021 to February 2023), Candid Therapeutics (acquired by UCB), ADARx Pharmaceuticals, Inc. (since 2023), Alkeus Pharmaceuticals, Inc. (since June 2023), Aviceda Therapeutics (since December 2024), Arbor Biotechnologies (from November 2021 to September 2025), Tarsus Pharmaceuticals (NASDAQ: TARS), Sagent Pharmaceuticals (NASDAQ: SGNT, acquired by Nichi I Ko), China Kanghui (NYSE:KH, acquired by Medtronic), Rempex (acquired by Medicines Company), Kala (NASDAQ:KALA), Surgical Specialties (acquired by GTCR), Sentre Heart (acquired by Atricure), NKF Pharma (SHA: 603707), Pathalys Pharma, Inc. (since August 2024), LB Pharma (from November 2023 to September 2025), Artios Pharma Ltd. (from July 2021 to September 2025), Corxel Pharmaceuticals Limited (since January 2026), and TCGX Asia Life Sciences Partners I, Ltd. (since May 2026). Dr. Yu has also served on several committees of boards of directors, including the Compensation Committee of LB Pharma (from November 2023 to September 2025), the Audit Committee of Arbor Biotechnologies (from November 2021 to September 2025), and the Nomination and Governance Committee of Artios Pharma Ltd. (from July 2021 to September 2025). While at Vivo, Dr. Yu also led investments in Zai Labs (NASDAQ: ZLAB), RiverVision (acquired by Horizon), CRISPR Therapeutics (NASDAQ:CRSP), Intellia (NASDAQ: NTLA), Durata (acquired by Actavis), Trauson (acquired by Stryker), and Revolution Medicines (NASDAQ:RVMD). Dr. Yu also serves on the California Board of Trustees for the Nature Conservancy (since August 2025) and ElevAATe Biotechnology (since November 2024), and was previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.
- Erez Chimovits
-
Erez Chimovits自2020年5月起担任Adarx Pharmaceuticals，Inc.董事会成员。Chimovits先生是投资公司OrbiMed的合伙人，自2010年11月以来，他在该公司担任过越来越多的职务。Chimovits先生目前在Upstream Bio，Inc.和几家私营公司的董事会任职。Chimovits先生此前曾在多家上市生物技术公司的董事会任职，包括从2016年1月至2021年3月的Adicet Bio公司、从2015年12月至2020年10月的BiomX公司、从2016年1月至2020年12月的LogicBio医疗，以及从2017年6月至2020年12月的Novus Therapeutics, Inc.，以及从2017年6月至2020年9月的TERM3，TERM3（现为Eledon Pharmaceuticals, Inc.）。在加入OrbiMed之前，Chimovits先生于2007年1月至2010年11月期间担任上市生物技术公司NasVax Ltd.（现为SciSparc Ltd.）的首席执行官。在此之前，Chimovits先生于2001年1月至2007年1月担任Compugen医疗美国公司总裁，该公司是一家上市生物技术公司Compugen Ltd.的子公司，并于1999年12月至2007年1月担任负责商业运营的执行副总裁。Chimovits先生在特拉维夫大学获得了微生物学学士学位、硕士学位和工商管理硕士学位。
Erez Chimovits has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since May 2020. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc.) from June 2017 until September 2020. Prior to joining OrbiMed, Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.), a public biotechnology company, from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., a public biotechnology company, from January 2001 to January 2007, and as Executive Vice President, Commercial Operations from December 1999 to January 2007. Mr. Chimovits earned his B.S., M.S. in Microbiology, and his M.B.A. from Tel Aviv University. - Erez Chimovits自2020年5月起担任Adarx Pharmaceuticals，Inc.董事会成员。Chimovits先生是投资公司OrbiMed的合伙人，自2010年11月以来，他在该公司担任过越来越多的职务。Chimovits先生目前在Upstream Bio，Inc.和几家私营公司的董事会任职。Chimovits先生此前曾在多家上市生物技术公司的董事会任职，包括从2016年1月至2021年3月的Adicet Bio公司、从2015年12月至2020年10月的BiomX公司、从2016年1月至2020年12月的LogicBio医疗，以及从2017年6月至2020年12月的Novus Therapeutics, Inc.，以及从2017年6月至2020年9月的TERM3，TERM3（现为Eledon Pharmaceuticals, Inc.）。在加入OrbiMed之前，Chimovits先生于2007年1月至2010年11月期间担任上市生物技术公司NasVax Ltd.（现为SciSparc Ltd.）的首席执行官。在此之前，Chimovits先生于2001年1月至2007年1月担任Compugen医疗美国公司总裁，该公司是一家上市生物技术公司Compugen Ltd.的子公司，并于1999年12月至2007年1月担任负责商业运营的执行副总裁。Chimovits先生在特拉维夫大学获得了微生物学学士学位、硕士学位和工商管理硕士学位。
- Erez Chimovits has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since May 2020. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc.) from June 2017 until September 2020. Prior to joining OrbiMed, Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.), a public biotechnology company, from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., a public biotechnology company, from January 2001 to January 2007, and as Executive Vice President, Commercial Operations from December 1999 to January 2007. Mr. Chimovits earned his B.S., M.S. in Microbiology, and his M.B.A. from Tel Aviv University.
- Zhen Li
-
Zhen Li是Adarx Pharmaceuticals，Inc.的创始成员之一，自Adarx Pharmaceuticals，Inc.于2019年12月成立以来一直担任Adarx Pharmaceuticals，Inc.的董事会成员，并自2020年1月起担任Adarx Pharmaceuticals，Inc.的总裁兼首席执行官。李博士还于2020年1月至2022年9月期间担任Adarx Pharmaceuticals，Inc.的首席财务官。李博士此前曾任职于上市药企Arrowhead Pharmaceuticals, Inc.（Arrowhead），担任化学&非临床开发高级副总裁。在加入Arrowhead之前，她曾在全球制药公司默克制药公司（默沙东）担任化学、RNAi疗法、过程化学总监。在任职于默沙东之前，她曾在先灵葆雅公司（一家制药公司（2009年被默沙东收购）和诺华公司担任领导职务，并领导小分子药物领域的药物开发团队。李博士曾任默沙东研究实验室化学主任，领导团队从事siRNA领域的研发工作。她在先灵葆雅从早期到后期领导了多个开发项目。李博士曾担任诺华创数的工艺和分析研发主管。李博士在北京大学获得学士学位，在哈佛大学获得化学和化学生物学博士学位。
Zhen Li is one of Adarx Pharmaceuticals, Inc.'s founding members and has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since Adarx Pharmaceuticals, Inc.'s inception in December 2019 and as Adarx Pharmaceuticals, Inc.'s President and Chief Executive Officer since January 2020. Dr. Li also was Adarx Pharmaceuticals, Inc.'s Chief Financial Officer from January 2020 to September 2022. Dr. Li previously worked at Arrowhead Pharmaceuticals, Inc. (Arrowhead), a public pharmaceutical company, serving as Senior Vice President, Chemistry & Non Clinical Development. Prior to joining Arrowhead, she served as Director of Chemistry, RNAi therapeutics, Process Chemistry at Merck & Co., Inc. (Merck), a global pharmaceutical company. Prior to her tenure at Merck, she held leadership positions at Schering Plough Corporation, a pharmaceutical company (acquired by Merck in 2009) and Novartis, and led teams in drug development in small molecule pharmaceuticals. Dr. Li was Director of Chemistry at Merck Research Laboratory and led a team in research and development in the field of siRNA. She led multiple development programs from early to late stage at Schering Plough. Dr. Li served as the Head of Process and Analytical Research & Development at Novartis Chuangshu. Dr. Li received her B.S. from Peking University and her Ph.D. in Chemistry and Chemical Biology from Harvard University. - Zhen Li是Adarx Pharmaceuticals，Inc.的创始成员之一，自Adarx Pharmaceuticals，Inc.于2019年12月成立以来一直担任Adarx Pharmaceuticals，Inc.的董事会成员，并自2020年1月起担任Adarx Pharmaceuticals，Inc.的总裁兼首席执行官。李博士还于2020年1月至2022年9月期间担任Adarx Pharmaceuticals，Inc.的首席财务官。李博士此前曾任职于上市药企Arrowhead Pharmaceuticals, Inc.（Arrowhead），担任化学&非临床开发高级副总裁。在加入Arrowhead之前，她曾在全球制药公司默克制药公司（默沙东）担任化学、RNAi疗法、过程化学总监。在任职于默沙东之前，她曾在先灵葆雅公司（一家制药公司（2009年被默沙东收购）和诺华公司担任领导职务，并领导小分子药物领域的药物开发团队。李博士曾任默沙东研究实验室化学主任，领导团队从事siRNA领域的研发工作。她在先灵葆雅从早期到后期领导了多个开发项目。李博士曾担任诺华创数的工艺和分析研发主管。李博士在北京大学获得学士学位，在哈佛大学获得化学和化学生物学博士学位。
- Zhen Li is one of Adarx Pharmaceuticals, Inc.'s founding members and has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since Adarx Pharmaceuticals, Inc.'s inception in December 2019 and as Adarx Pharmaceuticals, Inc.'s President and Chief Executive Officer since January 2020. Dr. Li also was Adarx Pharmaceuticals, Inc.'s Chief Financial Officer from January 2020 to September 2022. Dr. Li previously worked at Arrowhead Pharmaceuticals, Inc. (Arrowhead), a public pharmaceutical company, serving as Senior Vice President, Chemistry & Non Clinical Development. Prior to joining Arrowhead, she served as Director of Chemistry, RNAi therapeutics, Process Chemistry at Merck & Co., Inc. (Merck), a global pharmaceutical company. Prior to her tenure at Merck, she held leadership positions at Schering Plough Corporation, a pharmaceutical company (acquired by Merck in 2009) and Novartis, and led teams in drug development in small molecule pharmaceuticals. Dr. Li was Director of Chemistry at Merck Research Laboratory and led a team in research and development in the field of siRNA. She led multiple development programs from early to late stage at Schering Plough. Dr. Li served as the Head of Process and Analytical Research & Development at Novartis Chuangshu. Dr. Li received her B.S. from Peking University and her Ph.D. in Chemistry and Chemical Biology from Harvard University.
- Simeon George
-
Simeon George自2021年7月起担任Adarx Pharmaceuticals，Inc.董事会成员。乔治博士自2020年9月起担任跨大西洋医疗投资公司SROne Capital Management，LP的首席执行官和管理合伙人。乔治博士此前曾于2007年至2020年9月在生物技术风险投资公司葛兰素史克（GlaxoSmithKline plc）的间接全资子公司S.R. One，Limited（现称为GSK Equity Investments，Limited）担任过多个职务，最近于2018年1月至2020年9月担任首席执行官。George博士自2020年2月起担任上市生物技术公司Nkarta, Inc.的董事会成员，此前曾于2015年2月至2017年9月担任该等董事会成员，上市生物技术公司CRISPR Therapeutics AG自2015年3月起担任，上市生物技术公司Design Therapeutics, Inc.自2020年2月起担任。George博士此前曾于2011年2月至2020年9月担任生物制药公司Principia Biopharma Inc.（2020年被赛诺菲收购）的董事会成员，于2012年5月至2019年10月担任健康福利管理公司Progyny, Inc.，并于2017年5月至2022年8月担任上市生物制药公司Turning Point Therapeutics, Inc.（2022年被百时美施贵宝收购）的董事会成员。乔治博士在约翰霍普金斯大学获得神经科学学士学位，在宾夕法尼亚大学医学院获得医学博士学位，在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位（Mayer Scholar）。
Simeon George has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since July 2021. Dr. George has served as Chief Executive Officer and Managing Partner of SR One Capital Management, LP, a transatlantic healthcare investment firm, since September 2020. Dr. George previously served in various roles at S.R. One, Limited (now called GSK Equity Investments, Limited), an indirect, wholly owned subsidiary of GlaxoSmithKline plc, a biotechnology venture capital firm, from 2007 to September 2020, most recently serving as Chief Executive Officer from January 2018 to September 2020. Dr. George has served as a member of the board of directors of Nkarta, Inc., a public biotechnology company, since February 2020 and previously served on such board of directors from February 2015 to September 2017, CRISPR Therapeutics AG, a public biotechnology company, since March 2015 and Design Therapeutics, Inc., a public biotechnology company, since February 2020. Dr. George previously served as a member of the board of directors of Principia Biopharma Inc. (acquired by Sanofi in 2020), a biopharmaceutical company, from February 2011 to September 2020, Progyny, Inc., a health benefits management company, from May 2012 to October 2019, and Turning Point Therapeutics, Inc. (acquired by Bristol Myers Squibb in 2022), a public biopharmaceutical company, from May 2017 to August 2022. Dr. George received his B.A. in Neuroscience from Johns Hopkins University, his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania. - Simeon George自2021年7月起担任Adarx Pharmaceuticals，Inc.董事会成员。乔治博士自2020年9月起担任跨大西洋医疗投资公司SROne Capital Management，LP的首席执行官和管理合伙人。乔治博士此前曾于2007年至2020年9月在生物技术风险投资公司葛兰素史克（GlaxoSmithKline plc）的间接全资子公司S.R. One，Limited（现称为GSK Equity Investments，Limited）担任过多个职务，最近于2018年1月至2020年9月担任首席执行官。George博士自2020年2月起担任上市生物技术公司Nkarta, Inc.的董事会成员，此前曾于2015年2月至2017年9月担任该等董事会成员，上市生物技术公司CRISPR Therapeutics AG自2015年3月起担任，上市生物技术公司Design Therapeutics, Inc.自2020年2月起担任。George博士此前曾于2011年2月至2020年9月担任生物制药公司Principia Biopharma Inc.（2020年被赛诺菲收购）的董事会成员，于2012年5月至2019年10月担任健康福利管理公司Progyny, Inc.，并于2017年5月至2022年8月担任上市生物制药公司Turning Point Therapeutics, Inc.（2022年被百时美施贵宝收购）的董事会成员。乔治博士在约翰霍普金斯大学获得神经科学学士学位，在宾夕法尼亚大学医学院获得医学博士学位，在宾夕法尼亚大学沃顿商学院获得工商管理硕士学位（Mayer Scholar）。
- Simeon George has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since July 2021. Dr. George has served as Chief Executive Officer and Managing Partner of SR One Capital Management, LP, a transatlantic healthcare investment firm, since September 2020. Dr. George previously served in various roles at S.R. One, Limited (now called GSK Equity Investments, Limited), an indirect, wholly owned subsidiary of GlaxoSmithKline plc, a biotechnology venture capital firm, from 2007 to September 2020, most recently serving as Chief Executive Officer from January 2018 to September 2020. Dr. George has served as a member of the board of directors of Nkarta, Inc., a public biotechnology company, since February 2020 and previously served on such board of directors from February 2015 to September 2017, CRISPR Therapeutics AG, a public biotechnology company, since March 2015 and Design Therapeutics, Inc., a public biotechnology company, since February 2020. Dr. George previously served as a member of the board of directors of Principia Biopharma Inc. (acquired by Sanofi in 2020), a biopharmaceutical company, from February 2011 to September 2020, Progyny, Inc., a health benefits management company, from May 2012 to October 2019, and Turning Point Therapeutics, Inc. (acquired by Bristol Myers Squibb in 2022), a public biopharmaceutical company, from May 2017 to August 2022. Dr. George received his B.A. in Neuroscience from Johns Hopkins University, his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania.
- Judith J. Li
-
Judith J. Li于2021年9月至2026年9月期间担任Adarx Pharmaceuticals，Inc.董事会成员。李女士自2013年11月起担任生物医药风险投资公司LAV的合伙人。Li女士曾担任多家LAV投资组合公司的董事会成员，其中包括自2016年1月以来的生物技术公司Tmunity Therapeutics Incorporated（于2023年被上市生物技术公司Kite Pharma, Inc.收购）、自2020年12月以来的私营制药公司Scineuro Pharmaceuticals以及自2016年6月以来的生物技术公司Fortis Therapeutics。Li女士此前曾于2017年9月至2022年1月在上市生物技术公司Gritstone Oncology, Inc.担任董事会成员。Li女士此前还曾于2018年5月至2020年6月担任上市生物技术公司Inhibrx, Inc.的董事会成员，并于2015年12月至2020年9月担任上市生物制药公司NextCure, Inc.的董事会成员。李女士获得了哈佛大学生物学学士学位和哈佛商学院工商管理硕士学位。
Judith J. Li served as a member of Adarx Pharmaceuticals, Inc.'s board of directors from September 2021 to September 2026. Ms. Li has served as Partner at LAV, a biomedical venture capital firm, since November 2013. Ms. Li has served as a member of the board of directors of multiple LAV portfolio companies, including Tmunity Therapeutics Incorporated (acquired by Kite Pharma, Inc., a public biotechnology company, in 2023), a biotechnology company, since January 2016, Scineuro Pharmaceuticals, a private pharmaceutical company, since December 2020, and Fortis Therapeutics, a biotechnology company, since June 2016. Ms. Li previously served as a member of the board of directors at Gritstone Oncology, Inc., a public biotechnology company, from September 2017 to January 2022. Ms. Li has also previously served as a member of the board of directors of Inhibrx, Inc., a public biotechnology company, from May 2018 to June 2020, and Nextcure, Inc., a public biopharmaceutical company, from December 2015 to September 2020. Ms. Li received her B.A. in Biology from Harvard University and her M.B.A. from Harvard Business School. - Judith J. Li于2021年9月至2026年9月期间担任Adarx Pharmaceuticals，Inc.董事会成员。李女士自2013年11月起担任生物医药风险投资公司LAV的合伙人。Li女士曾担任多家LAV投资组合公司的董事会成员，其中包括自2016年1月以来的生物技术公司Tmunity Therapeutics Incorporated（于2023年被上市生物技术公司Kite Pharma, Inc.收购）、自2020年12月以来的私营制药公司Scineuro Pharmaceuticals以及自2016年6月以来的生物技术公司Fortis Therapeutics。Li女士此前曾于2017年9月至2022年1月在上市生物技术公司Gritstone Oncology, Inc.担任董事会成员。Li女士此前还曾于2018年5月至2020年6月担任上市生物技术公司Inhibrx, Inc.的董事会成员，并于2015年12月至2020年9月担任上市生物制药公司NextCure, Inc.的董事会成员。李女士获得了哈佛大学生物学学士学位和哈佛商学院工商管理硕士学位。
- Judith J. Li served as a member of Adarx Pharmaceuticals, Inc.'s board of directors from September 2021 to September 2026. Ms. Li has served as Partner at LAV, a biomedical venture capital firm, since November 2013. Ms. Li has served as a member of the board of directors of multiple LAV portfolio companies, including Tmunity Therapeutics Incorporated (acquired by Kite Pharma, Inc., a public biotechnology company, in 2023), a biotechnology company, since January 2016, Scineuro Pharmaceuticals, a private pharmaceutical company, since December 2020, and Fortis Therapeutics, a biotechnology company, since June 2016. Ms. Li previously served as a member of the board of directors at Gritstone Oncology, Inc., a public biotechnology company, from September 2017 to January 2022. Ms. Li has also previously served as a member of the board of directors of Inhibrx, Inc., a public biotechnology company, from May 2018 to June 2020, and Nextcure, Inc., a public biopharmaceutical company, from December 2015 to September 2020. Ms. Li received her B.A. in Biology from Harvard University and her M.B.A. from Harvard Business School.
- Ricky Sun
-
Ricky Sun于2023年8月至2026年9月期间担任Adarx Pharmaceuticals，Inc.董事会成员。2016年8月加入贝恩资本生命科学有限责任公司（Bain Capital），自2021年1月起担任合伙人。在加入贝恩资本之前，他于2013年至2016年在上市的生物技术公司Biogen Inc.担任企业发展和战略总监。在加入渤健之前，孙博士曾担任贝莱德的Alpha Strategies Group的Fundamental Equity Division成员以及贝莱德的Fundamental Large Cap Growth Equity Team的高级分析师，任职于贝莱德公司（贝莱德）的副总裁，覆盖医疗保健领域。在此之前，他曾在Citadel和Alyeska Investment Group担任高级医疗保健分析师，并曾在雷曼兄弟和摩根士丹利担任医药股票研究分析师。孙博士的职业生涯开始于上市制药公司Ironwood Pharmaceuticals, Inc.的高级科学家，在那里他参与了治疗肠易激综合征药物Linzess的发现和开发。孙博士此前曾于2018年12月至2022年2月担任上市生物技术公司Annexon, Inc.的董事会成员，于2018年8月至2021年9月担任上市生物技术公司Arcutis Biotherapeutics, Inc.的董事会成员，于2019年12月至2024年4月担任上市生物技术公司Savara，Inc.的董事会成员。孙博士在哈佛大学获得化学和化学生物学博士学位，曾是哈佛医学院生物化学和分子药理学的NIH博士后研究员。他还获得了纽约大学斯特恩商学院的工商管理硕士学位，在那里他是Mildred Elperin学者。他以优异成绩毕业于伯里亚学院，获得化学学士学位。
Ricky Sun served as a member of Adarx Pharmaceuticals, Inc.'s board of directors from August 2023 to September 2026. He joined Bain Capital Life Sciences, LP (Bain Capital) in August 2016 and has been a Partner since January 2021. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen Inc., a publicly held biotechnology company, from 2013 to 2016. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, Inc., (BlackRock) as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group and worked as a pharmaceuticals equity research analyst at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceuticals, Inc., a public pharmaceutical company, where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun previously served as a member of the board of directors of Annexon, Inc., a public biotechnology company, from December 2018 to February 2022, Arcutis Biotherapeutics, Inc., a public biotechnology company, from August 2018 to September 2021, and Savara, Inc., a public biotechnology company, from December 2019 to April 2024. Dr. Sun received his Ph.D. in Chemistry and Chemical Biology from Harvard University and was an NIH post doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received his M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in Chemistry. - Ricky Sun于2023年8月至2026年9月期间担任Adarx Pharmaceuticals，Inc.董事会成员。2016年8月加入贝恩资本生命科学有限责任公司（Bain Capital），自2021年1月起担任合伙人。在加入贝恩资本之前，他于2013年至2016年在上市的生物技术公司Biogen Inc.担任企业发展和战略总监。在加入渤健之前，孙博士曾担任贝莱德的Alpha Strategies Group的Fundamental Equity Division成员以及贝莱德的Fundamental Large Cap Growth Equity Team的高级分析师，任职于贝莱德公司（贝莱德）的副总裁，覆盖医疗保健领域。在此之前，他曾在Citadel和Alyeska Investment Group担任高级医疗保健分析师，并曾在雷曼兄弟和摩根士丹利担任医药股票研究分析师。孙博士的职业生涯开始于上市制药公司Ironwood Pharmaceuticals, Inc.的高级科学家，在那里他参与了治疗肠易激综合征药物Linzess的发现和开发。孙博士此前曾于2018年12月至2022年2月担任上市生物技术公司Annexon, Inc.的董事会成员，于2018年8月至2021年9月担任上市生物技术公司Arcutis Biotherapeutics, Inc.的董事会成员，于2019年12月至2024年4月担任上市生物技术公司Savara，Inc.的董事会成员。孙博士在哈佛大学获得化学和化学生物学博士学位，曾是哈佛医学院生物化学和分子药理学的NIH博士后研究员。他还获得了纽约大学斯特恩商学院的工商管理硕士学位，在那里他是Mildred Elperin学者。他以优异成绩毕业于伯里亚学院，获得化学学士学位。
- Ricky Sun served as a member of Adarx Pharmaceuticals, Inc.'s board of directors from August 2023 to September 2026. He joined Bain Capital Life Sciences, LP (Bain Capital) in August 2016 and has been a Partner since January 2021. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen Inc., a publicly held biotechnology company, from 2013 to 2016. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, Inc., (BlackRock) as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group and worked as a pharmaceuticals equity research analyst at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceuticals, Inc., a public pharmaceutical company, where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun previously served as a member of the board of directors of Annexon, Inc., a public biotechnology company, from December 2018 to February 2022, Arcutis Biotherapeutics, Inc., a public biotechnology company, from August 2018 to September 2021, and Savara, Inc., a public biotechnology company, from December 2019 to April 2024. Dr. Sun received his Ph.D. in Chemistry and Chemical Biology from Harvard University and was an NIH post doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received his M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in Chemistry.
- Ying Huang
-
Ying Huang自2026年7月起担任Adarx Pharmaceuticals，Inc.董事会成员。黄博士于2020年9月至2026年7月期间担任上市生物技术公司传奇生物技术公司的首席执行官，并于2019年7月至2022年5月期间担任首席财务官。黄博士还自2022年2月起担任私营生物制药公司Quanta Therapeutics，Inc.的董事，并自2024年9月起担任私营生物制药公司Third Arc Bio的董事。此前，黄博士于2014年8月至2019年7月担任美国银行证券公司董事总经理兼生物技术股票研究主管。黄博士于2007年开始担任生物技术分析师，在加入美国银行证券公司之前，曾任职于美联银行、瑞士信贷、Gleacher和巴克莱银行。在华尔街职业生涯之前，黄博士是先灵葆雅化学研究部的首席科学家，专注于心血管和中枢神经系统治疗领域的小分子药物发现。黄博士也是多项专利和同行评审出版物的共同作者。黄博士在哥伦比亚大学获得了化学硕士、哲学硕士和博士学位。黄博士还曾就读于哥伦比亚大学商学院和中国科技大学天才青年特别班。
Ying Huang has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since July 2026. Dr. Huang served as Chief Executive Officer of Legend Biotech Corporation, a public biotechnology company, from September 2020 to July 2026 and as Chief Financial Officer from July 2019 until May 2022. Dr. Huang has also served a director of Quanta Therapeutics, Inc., a private biopharmaceutical company, since February 2022, and a director of Third Arc Bio, a private biopharmaceutical company, since September 2024. Previously, Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. Dr. Huang is also the co author of multiple patents and peer reviewed publications. Dr. Huang received his M.A., M.Phil and Ph.D in Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China. - Ying Huang自2026年7月起担任Adarx Pharmaceuticals，Inc.董事会成员。黄博士于2020年9月至2026年7月期间担任上市生物技术公司传奇生物技术公司的首席执行官，并于2019年7月至2022年5月期间担任首席财务官。黄博士还自2022年2月起担任私营生物制药公司Quanta Therapeutics，Inc.的董事，并自2024年9月起担任私营生物制药公司Third Arc Bio的董事。此前，黄博士于2014年8月至2019年7月担任美国银行证券公司董事总经理兼生物技术股票研究主管。黄博士于2007年开始担任生物技术分析师，在加入美国银行证券公司之前，曾任职于美联银行、瑞士信贷、Gleacher和巴克莱银行。在华尔街职业生涯之前，黄博士是先灵葆雅化学研究部的首席科学家，专注于心血管和中枢神经系统治疗领域的小分子药物发现。黄博士也是多项专利和同行评审出版物的共同作者。黄博士在哥伦比亚大学获得了化学硕士、哲学硕士和博士学位。黄博士还曾就读于哥伦比亚大学商学院和中国科技大学天才青年特别班。
- Ying Huang has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since July 2026. Dr. Huang served as Chief Executive Officer of Legend Biotech Corporation, a public biotechnology company, from September 2020 to July 2026 and as Chief Financial Officer from July 2019 until May 2022. Dr. Huang has also served a director of Quanta Therapeutics, Inc., a private biopharmaceutical company, since February 2022, and a director of Third Arc Bio, a private biopharmaceutical company, since September 2024. Previously, Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. Dr. Huang is also the co author of multiple patents and peer reviewed publications. Dr. Huang received his M.A., M.Phil and Ph.D in Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China.
- Mary Tagliaferri
-
Mary Tagliaferri自2025年11月起担任Adarx Pharmaceuticals，Inc.董事会成员。Tagliaferri博士目前自2025年9月起担任上市生物制药公司内克塔治疗，Inc.的首席医疗官和高级副总裁，她还在2017年至2025年2月期间以相同身份任职，并自2015年1月起担任不同职务。Tagliaferri博士还自2024年8月起担任私营AI驱动的生物技术公司Iambic Therapeutics的董事会成员，并于2024年2月至2025年8月担任公共商业阶段生物制药公司Y MABS Therapeutics，Inc.的董事会成员。在此之前，Tagliaferri博士曾于2021年9月至2024年2月被百时美施贵宝收购之前在上市生物技术公司RayzeBio，Inc.的董事会任职，并于2020年11月至2024年8月在上市生物技术公司Enzo Biochem, Inc.的董事会任职。Tagliaferri博士在康奈尔大学获得农业经济和商业管理学士学位，在加州大学旧金山分校获得医学博士学位。
Mary Tagliaferri has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since November 2025. Dr. Tagliaferri currently serves as the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, Inc., a public biopharmaceutical company, since September 2025, where she also served in the same capacity from 2017 to February 2025 and in various roles since January 2015. Dr. Tagliaferri also has served on the board of directors of Iambic Therapeutics, a private AI driven biotechnology company, since August 2024, and on the board of directors of Y mAbs Therapeutics, Inc., a public commercial stage biopharmaceutical company, from February 2024 to August 2025. Prior to that, Dr. Tagliaferri served on the board of directors of RayzeBio, Inc., a public biotechnology company, from September 2021 until its acquisition by Bristol Myers Squibb in February 2024, and on the board of directors of Enzo Biochem, Inc., a public biotechnology company, from November 2020 to August 2024. Dr. Tagliaferri received her B.S. in Agricultural Economics and Business Management from Cornell University and her M.D. from the University of California, San Francisco. - Mary Tagliaferri自2025年11月起担任Adarx Pharmaceuticals，Inc.董事会成员。Tagliaferri博士目前自2025年9月起担任上市生物制药公司内克塔治疗，Inc.的首席医疗官和高级副总裁，她还在2017年至2025年2月期间以相同身份任职，并自2015年1月起担任不同职务。Tagliaferri博士还自2024年8月起担任私营AI驱动的生物技术公司Iambic Therapeutics的董事会成员，并于2024年2月至2025年8月担任公共商业阶段生物制药公司Y MABS Therapeutics，Inc.的董事会成员。在此之前，Tagliaferri博士曾于2021年9月至2024年2月被百时美施贵宝收购之前在上市生物技术公司RayzeBio，Inc.的董事会任职，并于2020年11月至2024年8月在上市生物技术公司Enzo Biochem, Inc.的董事会任职。Tagliaferri博士在康奈尔大学获得农业经济和商业管理学士学位，在加州大学旧金山分校获得医学博士学位。
- Mary Tagliaferri has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since November 2025. Dr. Tagliaferri currently serves as the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, Inc., a public biopharmaceutical company, since September 2025, where she also served in the same capacity from 2017 to February 2025 and in various roles since January 2015. Dr. Tagliaferri also has served on the board of directors of Iambic Therapeutics, a private AI driven biotechnology company, since August 2024, and on the board of directors of Y mAbs Therapeutics, Inc., a public commercial stage biopharmaceutical company, from February 2024 to August 2025. Prior to that, Dr. Tagliaferri served on the board of directors of RayzeBio, Inc., a public biotechnology company, from September 2021 until its acquisition by Bristol Myers Squibb in February 2024, and on the board of directors of Enzo Biochem, Inc., a public biotechnology company, from November 2020 to August 2024. Dr. Tagliaferri received her B.S. in Agricultural Economics and Business Management from Cornell University and her M.D. from the University of California, San Francisco.
- Ting Feng
-
廷锋于2025年10月至2026年9月担任Adarx Pharmaceuticals，Inc.董事会成员。冯博士自2022年1月起担任专门的医疗健康风险投资基金Sirona Capital的合伙人。在加入Sirona Capital之前，冯博士曾于2018年12月至2022年1月在医疗健康风险投资公司担任过各种投资职务，例如Lilly Asia Ventures（LAV），并于2016年至2018年在SAIF Partners担任过投资职务。冯博士目前自2021年11月起担任精准医疗公司Synnovation Therapeutics的董事会成员。冯博士此前曾于2019年11月至2022年3月担任上市药企上海艾力斯特医药股份有限公司董事会成员。冯博士还于2021年6月至2022年1月担任公共临床阶段生物制药公司Arrivent Biopharma的董事会成员。冯博士在武汉大学获得生物技术学士学位，在阿拉巴马大学伯明翰分校获得免疫学博士学位。
Ting Feng served as a member of Adarx Pharmaceuticals, Inc.'s board of directors from October 2025 to September 2026. Dr. Feng has served as Partner at Sirona Capital, a dedicated healthcare venture capital fund, since January 2022. Prior to joining Sirona Capital, Dr. Feng held various investment roles at healthcare venture firms, such as Lilly Asia Ventures (LAV), from December 2018 to January 2022, and SAIF Partners from 2016 to 2018. Dr. Feng currently serves as a member of the board of directors of Synnovation Therapeutics, a precision medicine company, since November 2021. Dr. Feng previously served as a member of the board of members of Shanghai Allist Pharmaceuticals Co., Ltd., a public pharmaceutical company, from November 2019 to March 2022. Dr. Feng also served as a member of the board of directors of ArriVent Biopharma, a public clinical stage biopharmaceutical company, from June 2021 to January 2022. Dr. Feng received her B.S. in Biotechnology from Wuhan University and her Ph.D. in Immunology from the University of Alabama at Birmingham. - 廷锋于2025年10月至2026年9月担任Adarx Pharmaceuticals，Inc.董事会成员。冯博士自2022年1月起担任专门的医疗健康风险投资基金Sirona Capital的合伙人。在加入Sirona Capital之前，冯博士曾于2018年12月至2022年1月在医疗健康风险投资公司担任过各种投资职务，例如Lilly Asia Ventures（LAV），并于2016年至2018年在SAIF Partners担任过投资职务。冯博士目前自2021年11月起担任精准医疗公司Synnovation Therapeutics的董事会成员。冯博士此前曾于2019年11月至2022年3月担任上市药企上海艾力斯特医药股份有限公司董事会成员。冯博士还于2021年6月至2022年1月担任公共临床阶段生物制药公司Arrivent Biopharma的董事会成员。冯博士在武汉大学获得生物技术学士学位，在阿拉巴马大学伯明翰分校获得免疫学博士学位。
- Ting Feng served as a member of Adarx Pharmaceuticals, Inc.'s board of directors from October 2025 to September 2026. Dr. Feng has served as Partner at Sirona Capital, a dedicated healthcare venture capital fund, since January 2022. Prior to joining Sirona Capital, Dr. Feng held various investment roles at healthcare venture firms, such as Lilly Asia Ventures (LAV), from December 2018 to January 2022, and SAIF Partners from 2016 to 2018. Dr. Feng currently serves as a member of the board of directors of Synnovation Therapeutics, a precision medicine company, since November 2021. Dr. Feng previously served as a member of the board of members of Shanghai Allist Pharmaceuticals Co., Ltd., a public pharmaceutical company, from November 2019 to March 2022. Dr. Feng also served as a member of the board of directors of ArriVent Biopharma, a public clinical stage biopharmaceutical company, from June 2021 to January 2022. Dr. Feng received her B.S. in Biotechnology from Wuhan University and her Ph.D. in Immunology from the University of Alabama at Birmingham.
- Carl L. Gordon
-
Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
- Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
高管简历
中英对照 | 中文 | 英文- Zhen Li
Zhen Li是Adarx Pharmaceuticals，Inc.的创始成员之一，自Adarx Pharmaceuticals，Inc.于2019年12月成立以来一直担任Adarx Pharmaceuticals，Inc.的董事会成员，并自2020年1月起担任Adarx Pharmaceuticals，Inc.的总裁兼首席执行官。李博士还于2020年1月至2022年9月期间担任Adarx Pharmaceuticals，Inc.的首席财务官。李博士此前曾任职于上市药企Arrowhead Pharmaceuticals, Inc.（Arrowhead），担任化学&非临床开发高级副总裁。在加入Arrowhead之前，她曾在全球制药公司默克制药公司（默沙东）担任化学、RNAi疗法、过程化学总监。在任职于默沙东之前，她曾在先灵葆雅公司（一家制药公司（2009年被默沙东收购）和诺华公司担任领导职务，并领导小分子药物领域的药物开发团队。李博士曾任默沙东研究实验室化学主任，领导团队从事siRNA领域的研发工作。她在先灵葆雅从早期到后期领导了多个开发项目。李博士曾担任诺华创数的工艺和分析研发主管。李博士在北京大学获得学士学位，在哈佛大学获得化学和化学生物学博士学位。
Zhen Li is one of Adarx Pharmaceuticals, Inc.'s founding members and has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since Adarx Pharmaceuticals, Inc.'s inception in December 2019 and as Adarx Pharmaceuticals, Inc.'s President and Chief Executive Officer since January 2020. Dr. Li also was Adarx Pharmaceuticals, Inc.'s Chief Financial Officer from January 2020 to September 2022. Dr. Li previously worked at Arrowhead Pharmaceuticals, Inc. (Arrowhead), a public pharmaceutical company, serving as Senior Vice President, Chemistry & Non Clinical Development. Prior to joining Arrowhead, she served as Director of Chemistry, RNAi therapeutics, Process Chemistry at Merck & Co., Inc. (Merck), a global pharmaceutical company. Prior to her tenure at Merck, she held leadership positions at Schering Plough Corporation, a pharmaceutical company (acquired by Merck in 2009) and Novartis, and led teams in drug development in small molecule pharmaceuticals. Dr. Li was Director of Chemistry at Merck Research Laboratory and led a team in research and development in the field of siRNA. She led multiple development programs from early to late stage at Schering Plough. Dr. Li served as the Head of Process and Analytical Research & Development at Novartis Chuangshu. Dr. Li received her B.S. from Peking University and her Ph.D. in Chemistry and Chemical Biology from Harvard University.- Zhen Li是Adarx Pharmaceuticals，Inc.的创始成员之一，自Adarx Pharmaceuticals，Inc.于2019年12月成立以来一直担任Adarx Pharmaceuticals，Inc.的董事会成员，并自2020年1月起担任Adarx Pharmaceuticals，Inc.的总裁兼首席执行官。李博士还于2020年1月至2022年9月期间担任Adarx Pharmaceuticals，Inc.的首席财务官。李博士此前曾任职于上市药企Arrowhead Pharmaceuticals, Inc.（Arrowhead），担任化学&非临床开发高级副总裁。在加入Arrowhead之前，她曾在全球制药公司默克制药公司（默沙东）担任化学、RNAi疗法、过程化学总监。在任职于默沙东之前，她曾在先灵葆雅公司（一家制药公司（2009年被默沙东收购）和诺华公司担任领导职务，并领导小分子药物领域的药物开发团队。李博士曾任默沙东研究实验室化学主任，领导团队从事siRNA领域的研发工作。她在先灵葆雅从早期到后期领导了多个开发项目。李博士曾担任诺华创数的工艺和分析研发主管。李博士在北京大学获得学士学位，在哈佛大学获得化学和化学生物学博士学位。
- Zhen Li is one of Adarx Pharmaceuticals, Inc.'s founding members and has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since Adarx Pharmaceuticals, Inc.'s inception in December 2019 and as Adarx Pharmaceuticals, Inc.'s President and Chief Executive Officer since January 2020. Dr. Li also was Adarx Pharmaceuticals, Inc.'s Chief Financial Officer from January 2020 to September 2022. Dr. Li previously worked at Arrowhead Pharmaceuticals, Inc. (Arrowhead), a public pharmaceutical company, serving as Senior Vice President, Chemistry & Non Clinical Development. Prior to joining Arrowhead, she served as Director of Chemistry, RNAi therapeutics, Process Chemistry at Merck & Co., Inc. (Merck), a global pharmaceutical company. Prior to her tenure at Merck, she held leadership positions at Schering Plough Corporation, a pharmaceutical company (acquired by Merck in 2009) and Novartis, and led teams in drug development in small molecule pharmaceuticals. Dr. Li was Director of Chemistry at Merck Research Laboratory and led a team in research and development in the field of siRNA. She led multiple development programs from early to late stage at Schering Plough. Dr. Li served as the Head of Process and Analytical Research & Development at Novartis Chuangshu. Dr. Li received her B.S. from Peking University and her Ph.D. in Chemistry and Chemical Biology from Harvard University.
- Ryan Fisk
Ryan Fisk自2026年3月起担任Adarx Pharmaceuticals，Inc.的首席财务官和首席商务官。此前，Fisk先生于2022年3月至2026年3月期间在投资银行高盛 Sachs担任董事总经理。2016年至2022年3月，Fisk先生曾在投资银行美银美林担任多个职务，包括2021年至2022年3月担任董事总经理，2016年至2020年担任董事和副总裁。在此之前，Fisk先生于2012年至2016年在投资银行瑞士信贷担任过各种职务，包括副总裁和合伙人。Fisk先生在加州大学洛杉矶分校获得经济学和政治学学士学位，在哥伦比亚商学院获得工商管理硕士学位。
Ryan Fisk has served as Adarx Pharmaceuticals, Inc.'s Chief Financial Officer and Chief Business Officer since March 2026. Previously, Mr. Fisk served as a Managing Director at Goldman Sachs, an investment bank, from March 2022 to March 2026. From 2016 to March 2022, Mr. Fisk served in various roles at Bank of America Merrill Lynch, an investment bank, including as a Managing Director from 2021 to March 2022 and as a Director and Vice President from 2016 to 2020. Prior to that, Mr. Fisk served in various roles at Credit Suisse, an investment bank, from 2012 to 2016, including as a Vice President and as an Associate. Mr. Fisk received his B.A. in Economics and Political Science from UCLA and his M.B.A. from Columbia Business School.- Ryan Fisk自2026年3月起担任Adarx Pharmaceuticals，Inc.的首席财务官和首席商务官。此前，Fisk先生于2022年3月至2026年3月期间在投资银行高盛 Sachs担任董事总经理。2016年至2022年3月，Fisk先生曾在投资银行美银美林担任多个职务，包括2021年至2022年3月担任董事总经理，2016年至2020年担任董事和副总裁。在此之前，Fisk先生于2012年至2016年在投资银行瑞士信贷担任过各种职务，包括副总裁和合伙人。Fisk先生在加州大学洛杉矶分校获得经济学和政治学学士学位，在哥伦比亚商学院获得工商管理硕士学位。
- Ryan Fisk has served as Adarx Pharmaceuticals, Inc.'s Chief Financial Officer and Chief Business Officer since March 2026. Previously, Mr. Fisk served as a Managing Director at Goldman Sachs, an investment bank, from March 2022 to March 2026. From 2016 to March 2022, Mr. Fisk served in various roles at Bank of America Merrill Lynch, an investment bank, including as a Managing Director from 2021 to March 2022 and as a Director and Vice President from 2016 to 2020. Prior to that, Mr. Fisk served in various roles at Credit Suisse, an investment bank, from 2012 to 2016, including as a Vice President and as an Associate. Mr. Fisk received his B.A. in Economics and Political Science from UCLA and his M.B.A. from Columbia Business School.
- Rui Zhu
Rui Zhu是创始成员，自2026年1月起担任Adarx Pharmaceuticals，Inc.的首席技术官，自2024年12月至2025年12月担任Adarx Pharmaceuticals，Inc.的高级副总裁，负责研究，自Adarx Pharmaceuticals，Inc.于2019年12月至2024年12月成立以来担任Adarx Pharmaceuticals，Inc.的研发副总裁。此前，朱博士曾在上市制药公司Arrowhead担任高级科学家，在那里他成功地共同领导了五个siRNA发现项目进入1期临床试验。朱博士获得南京大学化学学士学位，清华大学有机化学博士学位，并在耶鲁大学完成博士后研究。
Rui Zhu is a founding member and has served as Adarx Pharmaceuticals, Inc.'s Chief Technology Officer since January 2026, Adarx Pharmaceuticals, Inc.'s Senior Vice President, Research from December 2024 to December 2025 and Adarx Pharmaceuticals, Inc.'s Vice President, Research and Development since Adarx Pharmaceuticals, Inc.'s inception in December 2019 to December 2024. Previously, Dr. Zhu served as a senior scientist at Arrowhead, a public pharmaceutical company, where he successfully co led five siRNA discovery programs into Phase 1 clinical trials. Dr. Zhu received his B.S. in Chemistry from Nanjing University, his Ph.D. in Organic Chemistry from Tsinghua University and completed his postdoctoral research at Yale University.- Rui Zhu是创始成员，自2026年1月起担任Adarx Pharmaceuticals，Inc.的首席技术官，自2024年12月至2025年12月担任Adarx Pharmaceuticals，Inc.的高级副总裁，负责研究，自Adarx Pharmaceuticals，Inc.于2019年12月至2024年12月成立以来担任Adarx Pharmaceuticals，Inc.的研发副总裁。此前，朱博士曾在上市制药公司Arrowhead担任高级科学家，在那里他成功地共同领导了五个siRNA发现项目进入1期临床试验。朱博士获得南京大学化学学士学位，清华大学有机化学博士学位，并在耶鲁大学完成博士后研究。
- Rui Zhu is a founding member and has served as Adarx Pharmaceuticals, Inc.'s Chief Technology Officer since January 2026, Adarx Pharmaceuticals, Inc.'s Senior Vice President, Research from December 2024 to December 2025 and Adarx Pharmaceuticals, Inc.'s Vice President, Research and Development since Adarx Pharmaceuticals, Inc.'s inception in December 2019 to December 2024. Previously, Dr. Zhu served as a senior scientist at Arrowhead, a public pharmaceutical company, where he successfully co led five siRNA discovery programs into Phase 1 clinical trials. Dr. Zhu received his B.S. in Chemistry from Nanjing University, his Ph.D. in Organic Chemistry from Tsinghua University and completed his postdoctoral research at Yale University.
- A. Robert MacLeod
A. Robert MacLeod自2023年1月起担任Adarx Pharmaceuticals，Inc.的首席科学官。2021年9月至2022年12月，MacLeod博士在生物技术公司Flamingo Therapeutics，Inc.担任首席科学官。在此之前，MacLeod博士曾于2008年10月至2021年9月在上市生物技术公司伊奥尼斯制药公司担任多个职务，包括肿瘤学副总裁兼特许经营负责人、肿瘤学和探索性发现副总裁以及发现生物学执行董事。在他之前的职位上，MacLeod博士领导了几个多学科药物发现团队的战略和科学努力，导致了新的研究疗法的发现和临床开发，以及大量的科学出版物和专利。MacLeod博士在加拿大魁北克省蒙特利尔康考迪亚大学获得化学和生物化学学士学位，在麦吉尔大学获得癌症表观遗传学博士学位。
A. Robert MacLeod has served as Adarx Pharmaceuticals, Inc.'s Chief Scientific Officer since January 2023. From September 2021 to December 2022, Dr. MacLeod served as Chief Scientific Officer at Flamingo Therapeutics, Inc., a biotechnology company. Prior to that, Dr. MacLeod served in various roles at Ionis Pharmaceuticals, Inc., a public biotechnology company, from October 2008 to September 2021, including Vice President and Franchise Head of Oncology, Vice President of Oncology and Exploratory Discovery and Executive Director of Discovery Biology. In his prior positions, Dr. MacLeod led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of novel investigational therapeutics and numerous scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University Montreal, Quebec, Canada and his Ph.D. in Cancer Epigenetics from McGill University.- A. Robert MacLeod自2023年1月起担任Adarx Pharmaceuticals，Inc.的首席科学官。2021年9月至2022年12月，MacLeod博士在生物技术公司Flamingo Therapeutics，Inc.担任首席科学官。在此之前，MacLeod博士曾于2008年10月至2021年9月在上市生物技术公司伊奥尼斯制药公司担任多个职务，包括肿瘤学副总裁兼特许经营负责人、肿瘤学和探索性发现副总裁以及发现生物学执行董事。在他之前的职位上，MacLeod博士领导了几个多学科药物发现团队的战略和科学努力，导致了新的研究疗法的发现和临床开发，以及大量的科学出版物和专利。MacLeod博士在加拿大魁北克省蒙特利尔康考迪亚大学获得化学和生物化学学士学位，在麦吉尔大学获得癌症表观遗传学博士学位。
- A. Robert MacLeod has served as Adarx Pharmaceuticals, Inc.'s Chief Scientific Officer since January 2023. From September 2021 to December 2022, Dr. MacLeod served as Chief Scientific Officer at Flamingo Therapeutics, Inc., a biotechnology company. Prior to that, Dr. MacLeod served in various roles at Ionis Pharmaceuticals, Inc., a public biotechnology company, from October 2008 to September 2021, including Vice President and Franchise Head of Oncology, Vice President of Oncology and Exploratory Discovery and Executive Director of Discovery Biology. In his prior positions, Dr. MacLeod led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of novel investigational therapeutics and numerous scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University Montreal, Quebec, Canada and his Ph.D. in Cancer Epigenetics from McGill University.
- Robert Ackles
Robert Ackles自2026年8月起担任Adarx Pharmaceuticals，Inc.的首席人事官。在此之前，Ackles先生于2021年12月至2026年5月在上市生物制药公司Acadia Pharmaceuticals Inc.担任首席人事官。在此之前，在Acadia，Ackles先生于2016年12月至2021年12月担任人员与绩效（CHRO）副总裁，并于2014年6月至2016年12月担任培训与发展总监。在此之前，Ackles先生曾在生物制药公司Santarus, Inc.和生物制药公司TAP Pharmaceuticals，Inc.担任过各种职务。Ackles先生在加州大学圣巴巴拉分校获得了心理学学士学位。
Robert Ackles has served as Adarx Pharmaceuticals, Inc.'s Chief People Officer since August 2026. Previously, Mr. Ackles served as Chief People Officer at Acadia Pharmaceuticals Inc., a public biopharmaceutical company from December 2021 to May 2026. Preceding that, at Acadia, Mr. Ackles served as Vice President, People and Performance (CHRO) from December 2016 to December 2021, and as Director, Training and Development from June 2014 to December 2016. Prior to that, Mr. Ackles served in various roles at Santarus, Inc., a biopharmaceutical company, and TAP Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Ackles received his B.A. in Psychology from University of California, Santa Barbara.- Robert Ackles自2026年8月起担任Adarx Pharmaceuticals，Inc.的首席人事官。在此之前，Ackles先生于2021年12月至2026年5月在上市生物制药公司Acadia Pharmaceuticals Inc.担任首席人事官。在此之前，在Acadia，Ackles先生于2016年12月至2021年12月担任人员与绩效（CHRO）副总裁，并于2014年6月至2016年12月担任培训与发展总监。在此之前，Ackles先生曾在生物制药公司Santarus, Inc.和生物制药公司TAP Pharmaceuticals，Inc.担任过各种职务。Ackles先生在加州大学圣巴巴拉分校获得了心理学学士学位。
- Robert Ackles has served as Adarx Pharmaceuticals, Inc.'s Chief People Officer since August 2026. Previously, Mr. Ackles served as Chief People Officer at Acadia Pharmaceuticals Inc., a public biopharmaceutical company from December 2021 to May 2026. Preceding that, at Acadia, Mr. Ackles served as Vice President, People and Performance (CHRO) from December 2016 to December 2021, and as Director, Training and Development from June 2014 to December 2016. Prior to that, Mr. Ackles served in various roles at Santarus, Inc., a biopharmaceutical company, and TAP Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Ackles received his B.A. in Psychology from University of California, Santa Barbara.